The natural alternative to PEGylation
We have presented pre-clinical data that has demonstrated the extension of circulatory half-life of a number of therapeutically relevant proteins. Comparisons of fused vs. unfused molecules showed that all fusions were active and had a significantly extended half-life of between 5-74 fold i.v. and 4-12 s.c.
Extend the in vivo residence
In addition, antibody fragment (scFv) fusions have been shown to extend the in vivo residence time of the scFv whilst retaining their ligand binding properties.
Reduces dosage
One of our licensees (Human Genome Sciences Inc.) has also demonstrated the advantage of this fusion technology in the production of Albuferon™ – a fusion of albumin and interferon alpha. In human clinical studies Albuferon™ has been shown to be biologically active and has the potential to allow a less frequent dosing regime in comparison to a daily dosing regime for the unfused moiety.
